TRIM18 targets PP2A for proteasomal degradation and inhibits TFEB dephosphorylation and nuclear translocation, leading to autophagy inhibition and the development of an immune disorder (Di Rienzo et al., 2020). Here, PTPA is linked to immune system disorder.